The Computational Analysis Facility provides access to and expertise in high-performance computers and software for biological research in the institution. The facility, located on the thirteenth floor of the Houston Main Building, provides computer network access through Ethernet connections to all components of M.D. Anderson. Initially, the facility focused on computer support for the analysis of sequence data, including supplying the requisite programs for the manipulation of such data and database-searching technology. This support is being extended to providing software and expertise for molecular modeling of sequence data. While these types of analyses are necessary for conducting research in molecular biology today, few laboratories can afford to devote a person to the full- time activities required to remain current in this yield. Moreover, even few laboratories are able to support a person to find, install, and evaluate programs in the public domain that might be critical to one phase of research. Finally, few individual laboratories can afford the software licensing fees and the special computers required for analyses such as molecular modeling. Moreover, assistance with packages that are used only occasionally in a laboratory can be better obtained by a central resource facility like the CAF. At a lower level, the facility acts as a general ombudsman for general questions on computing and computers. Traditionally, the facility has measured its use by the number of central processing unit (CPU) hours used by all users. From December, 1993 to June, 1997, individuals in 21 Anderson departments used 3,866 CPU hours. In addition, the Facility teaches a graduate course on sequence analysis with a specific format making it easy for researchers to attend only the parts relevant to their research. This and other CAF activities are advertised through a newsletter and a World Wide Web page. In the future, the Facility will extend its computer support into related areas in which specialized software running on high-performance computers may be of use to a large number of users, such as three-dimensional analysis of confocal microscopy images obtained in the Automated Cytometry and Cell Sorter Laboratory/Confocal Microscopy and Image Analysis Facility. The policies of the Computational Analysis Facility are overseen by a committee comprised of Drs. de Crombrugghe, Marsha Frazier (Gastrointestinal Oncology and Digestive Diseases), and R. Allen White (biomathematics).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6506687
Study Section
Project Start
2001-09-28
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications